Thermalin Diabetes

Thermalin Diabetes, LLC is a Cleveland-based biotechnology company developing a portfolio of next generation insulin analogs for both the $8B rapid-acting and the $4B long acting insulin markets. Founded on compounds invented by Dr. Michael Weiss, Chairman of Biochemistry at Case Western Reserve Medical School, Thermalin’s therapeutic proteins will address medical needs related to diabetes and its complications.